Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,570 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
The bond market nearing threshold as long-term yields climb in a period of geopolitical tension and data surprises. T...
Jim Cramer asserts Five Below still has upside after a strong rally, driven by Winnie Park’s turnaround. The retailer...
NYSE has posted a listing for MSBT, a potential Morgan Stanley Bitcoin Trust. Market watchers say the bank’s first ba...
Morgan Stanley cuts Li Auto to a $22 price target while maintaining an upbeat view on margin recovery tied to the L9 ...
A Russian actor allegedly used forged ties to the Astor name to extract roughly $450 million from a Mexican billionai...
Apple reports strong Q2 2026 results, led by iPhone demand and Services, while signaling a shift toward ambient AI th...
Uber’s first-quarter results sparked a rare split on Wall Street: Goldman Sachs trims the stock target, while Piper S...
Bank of America signals a noticeable pullback in card use across its customers, adding to a growing picture of cautio...
Chasing big yields can be risky. This guide shows how to pursue want safe dividend income through careful screening, ...
A $222 million presale for Circle’s Arc token signals a strong institutional vote of confidence. Arc aims to underpin...
With a high-stakes Xi meeting on the horizon, President Trump has launched a calculated charm offensive, attracting t...